Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Malvern Completes Acquisition of MicroCal

Published: Friday, July 25, 2014
Last Updated: Friday, July 25, 2014
Bookmark and Share
Company announces purchase of Archimedes product from Affinity Biosensors.

Malvern Instruments Ltd has announced that it has completed the acquisition of MicroCal from GE Healthcare Life Sciences and has also purchased the Archimedes particle characterization system from Affinity Biosensors LLC (Santa Barbara, CA). Both of these developments extend Malvern’s portfolio of analytical solutions for the rapidly advancing biopharmaceutical industry.

The agreement to purchase GE Healthcare Life Sciences’ MicroCal business was announced on 4 June 2014 by Malvern’s parent company Spectris plc, and completion follows regulatory approval of the transaction.

MicroCal microcalorimeters are now part of the Malvern Instruments portfolio and are being sold and supported by Malvern Instruments with immediate effect. Users of MicroCal systems have been notified directly of any changes and full details of the product range are available on the Malvern website at

Malvern’s purchase of the Archimedes product from Affinity Biosensors follows two years of highly successful collaborative working between the two companies. In 2012, Malvern entered into an exclusive distribution agreement with Affinity Biosensors to market and sell Affinity Biosensors’ Archimedes particle characterization system in all geographies outside of North America, with a co-marketing agreement for North America itself.

Malvern has now acquired the Archimedes product designs and IP and a license to the underlying MIT patent for the technology for relevant fields of use. With this complete, Archimedes becomes a fully Malvern owned product and continues to be supported by the Malvern teams worldwide.

“I am delighted to be announcing the completion of Malvern’s acquisition of MicroCal from GE Healthcare Life Sciences and our purchase of the Archimedes system from Affinity Biosensors,” said Malvern’s Managing Director Paul Walker. “MicroCal microcalorimeters are an exciting and important new addition to Malvern’s portfolio that will significantly extend our ability to serve customers working in pharmaceutical and biopharmaceutical discovery, development and formulation. I’d like to welcome all our new MicroCal colleagues around the world, and look forward to the rapid and productive integration of our businesses.”

Paul Walker continued: “Affinity Biosensors’ Archimedes system has brought the technique of Resonant Mass Measurement into our range, and its close fit within our biopharmaceutical offering has encouraged us to secure its place and future development within Malvern. As part of our analytical toolkit for the biopharmaceutical industry, Archimedes sits alongside Zetasizer and NanoSight Nanoparticle Tracking Analysis systems, delivering a range of complementary solutions for quantifying early aggregation in bioformulations.”

Microcalorimetry is a tool that is used at almost every stage of the drug discovery, development and formulation process. MicroCal has more than 30 years’ experience in this field, with established ranges of differential scanning calorimeters (DSC) and isothermal titration calorimeters (ITC) all designed to meet the quality and productivity needs of today’s life science laboratories. These systems are an excellent fit with Malvern’s existing portfolio of measurement solutions for the pharmaceutical and biopharmaceutical industries. Their ability to deliver information about drug binding and protein stability is complementary to Malvern’s current products and to those in development.

Archimedes uses the technique of Resonant Mass Measurement to detect and count particles. It determines their mass and size with high resolution and accuracy in small sample volumes. A key area of application is the measurement of protein aggregation in biotherapeutic formulations, which provides critical information needed to speed development and improve drug safety and efficacy.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,200+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Malvern to Acquire MicroCal Business from GE
Malvern Instruments has entered into an agreement with GE Healthcare Life Sciences to acquire the company’s MicroCal™ microcalorimetry business.
Wednesday, June 04, 2014
Regional Growth Fund Success Sees Malvern Instruments Stepping up UK Recruitment
£3 million support from the UK Government’s Regional Growth Fund (RGF) will lead to the creation of 47 new jobs in the UK over the next five years.
Tuesday, May 20, 2014
Scientific News
Salford Lung Study - The First Real World Clinical Trial
In this podcast, we learn about the Salford Lung Study and its potential to revolutionize the way we assess new drugs and treatments around the world.
Nanoparticles Offer Promising Platform for Flavivirus Treatment
New nanoparticle effectively vaccinated mice against one dengue strain and could be created to target all four.
First Entirely 3D-printed Organ-on-a-Chip with Integrated Sensors
New approach to manufacturing may allow researchers to rapidly design organs-on-chips that match the properties of a specific disease or individual patient's cells.
Study Finds Key Regulator in Pulmonary Fibrosis
Researchers identify an enzyme that could open the way to therpies for chronic fatal lung disease.
Signaling Pathway Could Be Key to Improved Osteoporosis Treatment
Inhibition of SIK2 enzyme both stimulates bone formation and reduces bone breakdown in animal model.
Ovarian Cancer Insight
Study showed tumours release cytokines to attract macrophages, which secrete growth factors that in turn promote tumour growth.
Substance Can Potentially Postpone Aging
Researchers bridge the gap between two main aging theories - repairs to the DNA and poor functioning mitochondria.
Untangling Cause Of Memory Loss In Neurodegenerative Diseases
NIH-funded mouse study identifies a possible therapeutic target for a family of disorders.
New Model for Understanding Human Myeloma
Researchers develop mouse model where mice carry six human genes involved in human tumour growth.
Preventing Alzheimer's in Mice
Researchers have prevented the Alzheimer’s development in mice by using a virus delivery system to transport a specific gene into the brain.

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,200+ scientific videos